Syngene International Limited has appointed Jonathan Hunt as CEO-designate. He will take charge post the retirement of current CEO Peter Bains in March 2016 who will continue as a member of the Syngene Board.
Commenting on the new appointment, Kiran Mazumdar Shaw, managing director, Syngene International said, “We are extremely delighted to have Jonathan Hunt join the Syngene executive leadership team. After the resounding success of its IPO earlier during the year, Syngene is now at an exciting phase of its journey of transforming from a CRO to a full-fledged CRAMs player. Jonathan has a rich experience in the global biopharmaceutical industry and a proven track record of leading transformational change and delivering growth. We are sure, under his leadership, Syngene will continue to strengthen its position in the global CRAMs market.”
“Jonathan’s experience in building customer-focused organisations, coupled with his leadership and operational track record, make him the ideal selection for this position and we are delighted to welcome him aboard”, said Bains.
In his new role, Jonathan will be responsible for strengthening Syngene’s relations with its existing global customers as well as forging new relationships. He will also steer the company’s investments in developing and strengthening its capacities to augment the service offerings. Prior to Syngene, Jonathan had a long standing association with AstraZeneca and earlier in his career with Bayer Schering Pharma.